GlassScriptPhysician profile
Ronald Raffaele Rawitt
NPI 1760582555
$7,407.81
in general payments reported to CMS, 2019-2025
17 companies · $233 in 2025
The $233 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,948 · 2020: $617 · 2021: $1,922 · 2022: $311 · 2023: $794 · 2024: $582 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,610.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,609.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Validus Pharmaceuticals LLC | $1,534.98 | 2019-2023 | Equetro |
| Abbvie INC. | $1,345.25 | 2021-2025 | |
| Allergan, INC. | $1,060.04 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $953.41 | 2019-2024 | Trintellix |
| Ironshore Pharmaceuticals INC. | $517.68 | 2019 | |
| Axsome Therapeutics, INC. | $364.98 | 2023-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $364.34 | 2019 | |
| Bausch Health US, LLC | $355.40 | 2019-2023 | Aplenzin, Wellbutrin |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $174.99 | 2024 | Caplyta |
| Corium, LLC | $170.15 | 2022-2024 | Azstarys |
| Shire North American Group INC | $131.03 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $125.00 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $119.73 | 2019 | |
| Alkermes, INC. | $115.14 | 2023 | Lybalvi |
| Idorsia Pharmaceuticals US INC | $43.72 | 2023 | Quviviq |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $20.32 | 2022 | |
| Aprecia Pharmaceuticals, LLC | $11.65 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Rawitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.